Hinge Health Proves 3.0x ROI in Largest MSK Study

Hinge Health's largest-ever medical claims study confirms its digital MSK clinic delivers 3.0x ROI and $2,941 in annual savings per employer member over five years.

Lead

What Happened

The study analyzed five years of medical claims data spanning 2020 through 2024 for more than 200,000 commercially-insured adults aged 18 to 64 enrolled across nearly 1,000 employers operating in 23 distinct industries. The dataset is the broadest longitudinal evidence base assembled to date for any digital MSK platform.

Hinge Health members recorded 69% fewer surgical procedures, 61% fewer injection treatments, and 68% fewer diagnostic imaging scans compared with propensity-matched non-members. Surgery-related cost avoidance accounted for 52% of total savings, underscoring the program's capacity to redirect patients toward conservative, digitally delivered care and away from high-cost orthopedic interventions.

The five-year average Hinge Health ROI of 3.0x accelerated over the study period, reaching 3.14x in 2024 — indicating that clinical engagement and outcomes deepen as the platform matures within employer populations.

Study Methodology

Howden independently reviewed the methodology underpinning the analysis. The claims-based design compares total musculoskeletal medical expenditures for Hinge Health enrollees against propensity-matched controls receiving conventional care, isolating the platform's impact from demographic or health-status differences.

Coverage of nearly 1,000 employers across 23 industries addresses a longstanding critique of digital health outcomes research: that small, single-employer cohorts cannot be generalized to diverse commercial populations.

Strategic Context

Hinge Health went public on the NYSE in May 2025, raising $437.3 million at $32 per share and opening at $39.25 — a 23% first-day premium that signaled renewed institutional appetite for digital health companies with credible unit economics. The company reported net income of $17.1 million for the quarter ended March 31, 2025, its first profitable period as a public company.

The new ROI data arrives as self-insured employers and health plans face acute pressure to contain MSK care spending, which consistently ranks among the highest categories of commercial medical cost. Indirect costs from lost productivity and disability claims amplify the financial case for early intervention.

The shift toward digital MSK platforms reflects a broader employer strategy: deploying scalable, technology-mediated interventions that do not require proportional increases in provider headcount. Traditional in-person physical therapy remains constrained by geographic access and inconsistent outcomes measurement.

Competitive Position

Hinge Health operates alongside virtual physical therapy providers, on-demand musculoskeletal telehealth platforms, and integrated occupational health programs. The new study is approximately three times larger than the company's prior 136-employer analysis published in 2022 — which demonstrated 2.4x ROI — providing actuarially credible evidence for self-insured employer and health plan procurement cycles where scale and independent validation carry decisive weight.

Market Reaction

Shares of HNGE were active following the announcement. The company's market capitalization stood at approximately $4.71 billion at the time of the release. No updated revenue or earnings guidance was issued alongside the study.

Outlook

With Hinge Health ROI improving year-over-year and a five-year, nearly 1,000-employer evidence base now established, the company has materially raised the clinical and financial standard for the digital MSK category. Sustained surgery-avoidance rates at this scale position the platform as a defensible alternative to elective orthopedic procedures in commercial benefits design. The next validation test is whether comparable outcomes extend across Medicare and Medicaid populations, where the company has disclosed early-stage studies.

Analysis